Courtesy Think Progress, here’s a pretty good chart detailing the health program savings that were included in the White House’s opening bid on the fiscal slope. You can get this information from the White House’s FY2013 budget request.
|By: David Dayen Friday November 30, 2012 3:30 pm|
|By: David Dayen Monday August 27, 2012 9:45 am|
The substance of the Medicare debate in the 2012 election is completely at odds with the realities. The Romney campaign hammers away at the $716 billion in “Medicare cuts” imposed by the Affordable Care Act, designed to blunt a traditional Democratic advantage on the topic, as it did in 2010. So far this has worked; the last two national polls show the Romney-Ryan ticket aheadof Obama-Biden on the subject of Medicare.
|By: David Dayen Friday July 27, 2012 5:35 pm|
A couple judicial rulings recently actually went against corporate America in favor of consumers and residents, in such a rare fashion that I feel compelled to report on it.
|By: David Dayen Thursday May 24, 2012 4:00 pm|
The Senate has spent the day on a must-pass FDA bill that reauthorizes a user fee from drug companies to finance FDA operations, in addition to making other changes to how the FDA deals with drug shortages. The bill is primed for passage in the House, so if it can get through the Senate without much controversy, it’s pretty well assured of a trip to the President’s desk. Which means that it was time for another round of failure on the common-sense proposal to reimport cheap and safe pharmaceuticals from Canada and elsewhere.
|By: David Dayen Tuesday November 8, 2011 7:01 am|
Chief of Staff Bill Daley is giving up day-to-day operations at the White House, with Pete Rouse taking over. I’m not sure there’s anything else to the job other than day-to-day operations; that’s kind of what a Chief of Staff does, unless he’s the corporate bagman.
|By: David Dayen Monday October 31, 2011 2:45 pm|
The Obama Administration continued its “we can’t wait” initiative by ordering earlier notification of potential shortages and/or price gouging for medical drugs. But shortages and exorbitant prices are the natural outcomes of allowing drug monopolies and extended patent protection.
|By: David Dayen Thursday September 1, 2011 7:00 am|
Next week in Chicago, the Administration kicks off the eighth round of Trans-Pacific free trade agreement talks with multiple Asian nations. The nine-day negotiation includes talks with Vietnam, Brunei Darussalam, Singapore, Malaysia, New Zealand, Australia, Peru and Chile, but whatever comes out of the talks is intended to be a “docking agreement” to which larger nations in Asia and South America can sign up. That would include Japan, India and Taiwan; heck, it could include mainland China. This has been in the works for many years, and the Obama Administration has been negotiating since late 2009. The soft deadline for a Trans-Pacific FTA is November, just two months from now.
|By: David Dayen Saturday June 11, 2011 4:00 pm|
I’m so old I can remember when Lieberman wanted to expand Medicare. It was in 2009. He endorsed at that time a plan to lower the eligibility age for Medicare to 55 and allow people from 55 to 64 to buy into the program. Then he got wind that liberals liked that idea, and revoked his support, killing the idea when it was on the precipice of passing as part of the Affordable Care Act. Now, in this op-ed, he’s gone completely in the other direction, by endorsing a plan to “raise the Medicare eligibility age every year starting in 2014 by two months until it reaches 67 in 2025.”
|By: David Dayen Tuesday September 21, 2010 9:45 am|
In addition to having to fend off the slow chipping away of the health care law by the GOP, especially if they gain power over one or both houses of Congress, Democrats have to deal with the foxes they left in the henhouse, who are systematically working to preserve their own profits at the expense of consumers.
|By: David Dayen Monday August 30, 2010 2:30 pm|
Koch Industries and its two leaders, Charles and David, are not only out to destroy progressivism and restore Republican dominance in Washington, though that’s a side benefit. They are out to protect their company’s financial industries, which run the gamut of practically every major policy the Obama Administration has tackled this year.